CYTOKERATIN 19 IMMUNOREACTIVITY IN PAPILLARY THYROID CARCINOMA.

Sahoo S, Hoda SA, Rosai J, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 2001;116(5):696–702.         

Bose D, Das RN, Chatterjee U, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Indian J Med Paediatr Oncol 2012;33(2):107-11.

Negri E, Dal Maso L, Ron E, et al. A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control 1999;10(2):143–55.               

DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and genetics of tumours of endocrine organs. In: Kleihues P, Sobrin LH, (eds). World Health Organization. Classification of tumours. Lyon: IARC Press, 2004:49-66.

Sharma C. An analysis of trends of incidence and cytohistological correlation of papillary carcinoma of the thyroid gland with evaluation of discordant cases. J Cytol 2016;33(4):192-8.            

Alshenawy HA. Utility of immunohistochemical markers in differential diagnosis of follicular cell derived thyroid lesions. Journal of Microscopy and Ultrastructure 2014;2(3):127-36.                  

Tamimi DM. The association between chronic lymphocytic thyroiditis and thyroid tumors. Int J Surg Pathol 2002;10(2):141-6.            

Saleh HA, Jin B, Barnwell J, et al. Utility of IHC markers in differentiating benign from malignant follicular derived thyroid nodules. Diagn Pathol 2010;5:9.